INTRODUCTION:
To get sustained release of the drug is aimed to decrease the dose and dosing frequency and so its side effects. Sustained-release formulations may be administered once or twice daily 1 . The multilayered tablet concept has been long utilized to develop sustained release formulations. Such a tablet has a fast releasing layer and may contain bior triple layers to sustain the drug release. The pharmacokinetic advantage relies on the fact that drug release from fast releasing granules leads to a sudden rise in the blood concentration. However, the blood level is maintained at steady state as the drug is released from the sustaining granules. Among the different polymers, Eudragit and Hydroxypropylmethylcellulose have been used successfully to obtain appropriate sustained release matrix formulations.
Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. The drug also has relatively short plasma elimination half life of 1.5 to 4.5 hours 7, 8 .So SR products are needed for metformin to prolong its duration of action and improve patient compliance 2, 3 .
Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent. pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic β cells.
MATERIAL
MetforminHCl and pioglitazoneHCl were provided as gift sample Bharat PrenteralsLtd. Baroda,India. Hydroxypropylmethylcellulosee15, hydroxypropylmethylcelluloseK100, carbopol934, ethylcellulose, PVPK30, microcrystallinecellulose, sodium bicarbonate, citric acid, magnesium stearate and talc of analytical grade were purchased from National Chemicals, Mumbai. Isopropyl alcohol of analytical grade was purchased from Sigma Eldrich, Mumbai and used without any further purification
METHODS
Preparation of bilayered tablet: Bilayer tablet of MetforminHCl and Pioglitazine was developed in three different stages. Sustained release layer of MetforminHCl was prepared by wet granulation using solution of PVPK30 in isopropyl alcohol and immediate release layer of PioglitazoneHCl was optimized separately by direct compression technique. After optimization of individual layers, the bilayer tablet was prepared where immediate release layer was compression coated on optimized tablet of MetforminHCl.
Swelling index: The swelling index of tablets was determined in 0.1N HCl (pH 1.2) at room temperature. The swollen weight of the tablet was determined at predefined time intervals over a period of 10h. The swelling index (SI), expressed as a percentage, and was calculated from the following equation SI = {(Mt-Mo)/Mo} X 100; Where,
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In-vitro buoyancy studies: In-vitro buoyancy studies were performed for all the formulations as per the method described by Rosa et al. The randomly selected tablets from each formulation were kept in a 100ml beaker containing simulated gastric fluid, pH1.2 as per USP. The time taken for the tablet to rise to the surface and float was taken as floating lag time (FLT). The duration of time the dosage form constantly remained on the surface of medium was determined as the total floating time (TFT).
Release rate study: The release rate of MetforminHCl from floating tablets was determined USP dissolution testing apparatus type I (Basket method) and that of PioglitazoneHCl in USP dissolution testing apparatus type II. The dissolution test was performed using 900 ml of 0.1N hydrochloric acid, at 37 ± 0.5°C and 50rpm. A sample (5ml) of the solution was withdrawn from the dissolution apparatus hourly and the samples were replaced with fresh dissolution medium. The samples were filtered through a 0.45μ membrane filter and diluted to a suitable concentration with 0.1N hydrochloric acid. Absorbance of these solutions was measured at 232nm (for metforminHCl) and 268nm (for pioglitazoneHCl) using a UV/Visible spectrophotometer. The percentage drug release was plotted against time to determine the release profile
RESULTS AND DISCUSSION:
All the formulations given in table 1 and 3 were formulated.Once daily dosage form of sustained release MetforminHCl and immediate release PioglitazoneHCl tablets were formed they were evaluated for various physical properties individualy and the values are shown in the table 2 and 4 respectively. As swlling polymers are used to sustain the release swelling indexes 6 were obtained for 10hrs and their results are given in table 2. Figure 1 and 2 shows the dissolution profile of MetforminHCl sustained release tablets and PioglitazoneHCl immediate release tablet. 150  100  50  50  75  100  150  100  50  HPMC K100  50  100  150  100  75  50  50  100  15015  15  15  15  15  15  MCC  52  52  52  02  02  02  02  02  02  Mg. stearate  5  5  5  5  5  5  5  5  5  Talc  3  3  3  3  3  3  3  3  3  Total  850  850  850  850  850  850  850  850  850  Table 2 
Figure 1 Dissolution comparision of all metformin sustained release tablet
From above all formulations of metformin tablets M9 showing desirable sustained release for 10 hrs so it is concluded as optimized batch. For immediate layer of PioglitazoneHCl, we used crospovidone as superdisintegrant. In above formulations P1, P2 and P3 crospovidone was used in concentration of 3%, 5%, and 7% respectively.
From it can be told that formulation P2 and P3 released 85% of drug within 15 min which is desirable. Hence Batch P2 with 5% of crospovidone was optimizesd. Here 5% of crospovidone was selected because it was recommended by literature & 7% crospovidone was rejected.
The drug release data of MetforminHCl and PioglitazoneHCl were fitted to models representing zero order, first order, Higuchi's and Korsmeyer's equation 9 kinetics to know the release mechanisms. The data were processed for regression analysis using MS EXCEL 2007 statistical function. The results are shown in Table 5 .
In the present study, in vitro release profiles could be best expressed by Higuchi's equation as optimized formulation (M9P2) showed good linearity (R 2 : 0.975) indicates that diffusion is dominant mechanism of drug release with this formulation 4, 5 .
After evaluating all the batches M9P2 is optimized and so final formulation of bilayer tablet is given in table 7 and its evaluation date is given in table 8. 
CONCLUSION:
HPMCE15, HPMCK100 and carbopol934P were used as matrix forming polymer for the preparation of MetforminHCl sustained release layer which enabled drug release from 5 to 10hrs in different proportion of matrix polymers with near to zero order release profile and diffusion as preliminary release mechanism. PioglitazoneHCl immediate release layer was prepared using crosspovidone in different proportion where 3% was found promising which disintegrates completely within 4min. The core tablet of MetforminHCl in bilayered tablet was prepared by wet granulation and immediate release layer of PioglitazoneHCl was compression coated on it. The optimized bilayered tablet can be used as combination therapy for diabetes which reduses dosing frequency and improves patient compliance. Pioglitazone release shows that the dissolution rate of Pioglitazone can be enhanced considerably by using crosspovidone as super disintegrent.
SR fixed dose bilayer matrix tablets containing 500mgMetforminHCl as SR from one layer and 15mg Piogleitazone as from another layer can be successfully formulated.
